Olympus Competitors

Sanofi (NASDAQ:SNY) and Olympus (OTCMKTS:OCPNY) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, valuation, dividends and profitability.

Institutional and Insider Ownership

6.9% of Sanofi shares are owned by institutional investors. Comparatively, 0.1% of Olympus shares are owned by institutional investors. 1.0% of Sanofi shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Volatility & Risk

Sanofi has a beta of 0.55, suggesting that its share price is 45% less volatile than the S&P 500. Comparatively, Olympus has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500.

Profitability

This table compares Sanofi and Olympus' net margins, return on equity and return on assets.

Dividends

Sanofi pays an annual dividend of $1.17 per share and has a dividend yield of 2.5%. Olympus pays an annual dividend of $0.07 per share and has a dividend yield of 0.3%. Sanofi pays out 35.2% of its earnings in the form of a dividend. Olympus pays out 19.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Analyst Ratings

This is a breakdown of recent recommendations for Sanofi and Olympus, as reported by MarketBeat.

Valuation & Earnings

This table compares Sanofi and Olympus' revenue, earnings per share and valuation.

Sanofi has higher revenue and earnings than Olympus. Sanofi is trading at a lower price-to-earnings ratio than Olympus, indicating that it is currently the more affordable of the two stocks.

Summary

Sanofi beats Olympus on 10 of the 16 factors compared between the two stocks.

CSL (OTCMKTS:CSLLY) and Olympus (OTCMKTS:OCPNY) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, valuation, dividends and profitability.

Institutional and Insider Ownership

0.2% of CSL shares are owned by institutional investors. Comparatively, 0.1% of Olympus shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Volatility & Risk

CSL has a beta of 0.59, suggesting that its share price is 41% less volatile than the S&P 500. Comparatively, Olympus has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500.

Profitability

This table compares CSL and Olympus' net margins, return on equity and return on assets.

Dividends

CSL pays an annual dividend of $0.97 per share and has a dividend yield of 0.9%. Olympus pays an annual dividend of $0.07 per share and has a dividend yield of 0.3%. CSL pays out 42.0% of its earnings in the form of a dividend. Olympus pays out 19.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Analyst Ratings

This is a breakdown of recent recommendations for CSL and Olympus, as reported by MarketBeat.

Valuation & Earnings

This table compares CSL and Olympus' revenue, earnings per share and valuation.

CSL has higher revenue and earnings than Olympus. CSL is trading at a lower price-to-earnings ratio than Olympus, indicating that it is currently the more affordable of the two stocks.

Summary

Olympus beats CSL on 8 of the 15 factors compared between the two stocks.

Stryker (NYSE:SYK) and Olympus (OTCMKTS:OCPNY) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, valuation, dividends and profitability.

Volatility & Risk

Stryker has a beta of 0.87, suggesting that its share price is 13% less volatile than the S&P 500. Comparatively, Olympus has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500.

Valuation & Earnings

This table compares Stryker and Olympus' revenue, earnings per share and valuation.

Stryker has higher revenue and earnings than Olympus. Stryker is trading at a lower price-to-earnings ratio than Olympus, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations for Stryker and Olympus, as reported by MarketBeat.

Stryker currently has a consensus target price of $231.00, indicating a potential downside of 5.86%. Given Stryker's higher probable upside, equities analysts clearly believe Stryker is more favorable than Olympus.

Dividends

Stryker pays an annual dividend of $2.52 per share and has a dividend yield of 1.0%. Olympus pays an annual dividend of $0.07 per share and has a dividend yield of 0.3%. Stryker pays out 30.5% of its earnings in the form of a dividend. Olympus pays out 19.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Stryker has raised its dividend for 1 consecutive years. Stryker is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Institutional and Insider Ownership

71.5% of Stryker shares are owned by institutional investors. Comparatively, 0.1% of Olympus shares are owned by institutional investors. 6.8% of Stryker shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Stryker and Olympus' net margins, return on equity and return on assets.

Summary

Stryker beats Olympus on 14 of the 17 factors compared between the two stocks.

Olympus (OTCMKTS:OCPNY) and Intuitive Surgical (NASDAQ:ISRG) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, profitability and dividends.

Risk & Volatility

Olympus has a beta of 0.68, indicating that its share price is 32% less volatile than the S&P 500. Comparatively, Intuitive Surgical has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500.

Earnings & Valuation

This table compares Olympus and Intuitive Surgical's gross revenue, earnings per share (EPS) and valuation.

Intuitive Surgical has lower revenue, but higher earnings than Olympus. Olympus is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings for Olympus and Intuitive Surgical, as reported by MarketBeat.com.

Intuitive Surgical has a consensus price target of $736.75, indicating a potential downside of 1.77%. Given Intuitive Surgical's higher probable upside, analysts clearly believe Intuitive Surgical is more favorable than Olympus.

Insider & Institutional Ownership

0.1% of Olympus shares are owned by institutional investors. Comparatively, 86.5% of Intuitive Surgical shares are owned by institutional investors. 1.6% of Intuitive Surgical shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Olympus and Intuitive Surgical's net margins, return on equity and return on assets.

Summary

Intuitive Surgical beats Olympus on 12 of the 15 factors compared between the two stocks.

Olympus (OTCMKTS:OCPNY) and GlaxoSmithKline (NYSE:GSK) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, profitability and dividends.

Volatility and Risk

Olympus has a beta of 0.68, indicating that its stock price is 32% less volatile than the S&P 500. Comparatively, GlaxoSmithKline has a beta of 0.67, indicating that its stock price is 33% less volatile than the S&P 500.

Valuation and Earnings

This table compares Olympus and GlaxoSmithKline's top-line revenue, earnings per share and valuation.

GlaxoSmithKline has higher revenue and earnings than Olympus. GlaxoSmithKline is trading at a lower price-to-earnings ratio than Olympus, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings for Olympus and GlaxoSmithKline, as reported by MarketBeat.com.

Dividends

Olympus pays an annual dividend of $0.07 per share and has a dividend yield of 0.3%. GlaxoSmithKline pays an annual dividend of $2.48 per share and has a dividend yield of 7.3%. Olympus pays out 19.4% of its earnings in the form of a dividend. GlaxoSmithKline pays out 78.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. GlaxoSmithKline has raised its dividend for 1 consecutive years. GlaxoSmithKline is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Institutional and Insider Ownership

0.1% of Olympus shares are held by institutional investors. Comparatively, 11.8% of GlaxoSmithKline shares are held by institutional investors. 10.0% of GlaxoSmithKline shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Olympus and GlaxoSmithKline's net margins, return on equity and return on assets.

Summary

GlaxoSmithKline beats Olympus on 11 of the 17 factors compared between the two stocks.

Olympus (OTCMKTS:OCPNY) and Gilead Sciences (NASDAQ:GILD) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, profitability and dividends.

Volatility and Risk

Olympus has a beta of 0.68, indicating that its stock price is 32% less volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500.

Valuation and Earnings

This table compares Olympus and Gilead Sciences' top-line revenue, earnings per share and valuation.

Gilead Sciences has higher revenue and earnings than Olympus. Gilead Sciences is trading at a lower price-to-earnings ratio than Olympus, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings for Olympus and Gilead Sciences, as reported by MarketBeat.com.

Gilead Sciences has a consensus price target of $96.0370, indicating a potential upside of 52.42%. Given Gilead Sciences' higher probable upside, analysts clearly believe Gilead Sciences is more favorable than Olympus.

Dividends

Olympus pays an annual dividend of $0.07 per share and has a dividend yield of 0.3%. Gilead Sciences pays an annual dividend of $2.72 per share and has a dividend yield of 4.3%. Olympus pays out 19.4% of its earnings in the form of a dividend. Gilead Sciences pays out 44.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Gilead Sciences has raised its dividend for 1 consecutive years. Gilead Sciences is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Institutional and Insider Ownership

0.1% of Olympus shares are held by institutional investors. Comparatively, 76.4% of Gilead Sciences shares are held by institutional investors. 0.1% of Gilead Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Olympus and Gilead Sciences' net margins, return on equity and return on assets.

Summary

Gilead Sciences beats Olympus on 12 of the 18 factors compared between the two stocks.